How have population studies used IIEF-5 to map age-related prevalence and which comorbidities most strongly correlate with low IIEF-5 scores?
Executive summary
Population studies have deployed the five-item International Index of Erectile Function (IIEF‑5) both as a screening instrument in representative surveys and as a standardized outcome in clinic‑ and registry‑based cohorts to map ED prevalence across single years of age and age bands, consistently showing rising prevalence and severity with increasing age [1] [2] [3] [4]. Those same studies identify vascular and metabolic comorbidities—diabetes, hypertension, dyslipidemia, obesity and cardiovascular disease—plus overall comorbidity burden and hypogonadism as the strongest, most reproducible correlates of lower IIEF‑5 scores, while also flagging methodologic limits (self‑report, sexual activity criteria, cross‑sectional design) that complicate causal inference [5] [6] [3] [7] [1].
1. How IIEF‑5 is used in population research: standardization and sampling
Large nationally representative and clinic‑based studies have relied on the validated IIEF‑5 to produce comparable ED prevalence estimates and to link erectile function to age and health status; the 2021 National Survey of Sexual Wellbeing used IIEF‑5 to estimate national ED prevalence and to describe comorbidities and barriers to care [1], while institutional registries have applied IIEF domains to tens of thousands of men to derive age‑specific probabilities rather than broad age bins [2].
2. Mapping prevalence by age: granular age curves, not just decades
Researchers have moved beyond coarse 5–10‑year bands by using large samples to estimate ED probability at specific ages, demonstrating stable rates in younger adult decades and then progressive increases after midlife—examples include MSKCC data showing finer age‑stratified prevalences [2] and classical population work that documented ED rising from ~26–29% in men aged 20–50 to >70% in men 71–80 [3] [4].
3. Severity trends: how IIEF‑5 tracks worsening dysfunction with age
IIEF‑5 categories permit tracking of severity as well as prevalence; population samples have shown severe ED (IIEF‑5 5–7) to be vanishingly rare below middle age and to rise substantially in the oldest groups (example: severe ED climbing to ~9.6% in 71–80‑year‑olds) [3] [4], providing clinicians and policymakers with both population burden and clinical‑severity context.
4. Comorbidities most strongly tied to low IIEF‑5: vascular and metabolic drivers
Across cross‑sectional studies and surveys, diabetes, hypertension, dyslipidemia, atherosclerotic and coronary artery disease, and obesity consistently correlate with lower IIEF‑5 scores and higher ED prevalence, reflecting underlying endothelial and vascular pathology as dominant drivers of erectile dysfunction in population data [6] [3] [4] [8].
5. Aggregate measures and hormones: comorbidity indices and hypogonadism
Studies that use aggregate comorbidity indices—such as the Charlson/modified Charlson Comorbidity Index—find higher comorbidity burden independently associated with worse IIEF‑5 scores [5] [2], and several clinic cohorts report that low testosterone or hypogonadism show negative correlations with IIEF‑5 in univariate and multivariable models, though the strength and independence of that relationship varies by study [5] [7].
6. Methodologic caveats and competing interpretations
Population findings are robust in direction but limited in causal reach: most evidence is cross‑sectional, IIEF‑5 administration often excludes men who have not been sexually active recently (a source of underestimation), and web‑ or clinic‑based sampling can bias prevalence and comorbidity patterns; critiques note pandemic timing and sampling mode may alter recent estimates and that symptoms, distress and health behaviors mediate observed associations [1] [9]. Alternative interpretations—psychogenic contributions, medication effects, and selection bias in clinical cohorts—are explicitly raised in the literature and temper claims that age alone explains most IIEF‑5 decline [1] [10].
7. What this means for clinicians and public health
IIEF‑5–based population mapping makes clear that erectile dysfunction is common and age‑linked but that its strongest correlates are modifiable vascular and metabolic comorbidities plus overall illness burden; therefore, preventive and therapeutic strategies that target diabetes, hypertension, dyslipidemia, obesity and smoking are the logical public‑health levers suggested by these observational maps, even as randomized or longitudinal data are needed to prove reversibility of IIEF‑5 declines [6] [3] [5].